LIMN
Liminatus Pharma, Inc.
$0.14
+0.03 (+24.35%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$6.66M
Shares
44,877,633
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.14
Open$0.17
Day$0.13–0.21
52W$0.10–10.75
Avg vol 30d34.8M
Short int910K · 2.0% float · 1.0d
Short vol56%
DataMay 2025–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−78% below
−
Price vs 50-day avg
−13% below
◦
RSI (14)
53 · neutral
+
MACD trend
positive
−
52-week position
0% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $0 › 200d $1 — 200d above 50d
+
Institutional flow
+25% holders QoQ · +6 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
2.03% of float · ▼ -25.9% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
15 holders — near 1-yr high, broad support
Fundamentals
Poor
−
EPS growth
−115% Y/Y
−
Free cash flow
$-10.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−78% below
Bearish
Price vs 50-day avg
−13% below
Bearish
RSI (14)
53 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
0% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.03% of float · ▼ -25.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
15 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $11
vs 200-day avg -78%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIMN
this stock
Liminatus Pharma, Inc.
|
$6.66M | -76.6% | — | — | 2.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIMN | +44.4% | -5.9% | -82.6% | +30.0% | -76.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +43.0% | -4.7% | -90.6% | +30.3% | -85.8% |
Key facts
CIK
1971387
CUSIP
53271X108